Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUSP3 | P51452 | 1/20 | 0.66 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.66 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | NPC1 | O15118 | 3/20 | 0.65 |
| ▸ | RAB9A | P51151 | 3/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | FAAH | O00519 | 1/20 | 0.62 |
| ▸ | MGLL | Q99685 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20834535 | 1.00 | DUSP3 (0.66) | DUSP3PTPN5PTPN11LMNANPC1 | |
| SCHEMBL19449700 | 0.91 | FAAH (0.57) | DUSP3PTPN5PTPN11LMNANPC1 | |
| SCHEMBL28642848 | 0.86 | NPC1 (0.61) | LMNANPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL17560748 | 0.86 | NPC1 (0.61) | LMNANPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL17560750 | 0.86 | NPC1 (0.61) | LMNANPC1RAB9AMAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL21519598 | 0.84 | NPC1 (0.60) | LMNANPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL11386820 | 0.83 | LMNA (0.71) | LMNANPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL13475713 | 0.83 | NPC1 (0.81) | LMNANPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL11386823 | 0.83 | LMNA (0.71) | LMNANPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL19449730 | 0.81 | NPC1 (0.58) | LMNANPC1RAB9AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170291886-A1 | METHODS FOR TREATING PROTOZOAN INFECTIONS | NEOCULI PTY LTD (AU) | 2017-10-12 | — | — | US | claimed |
| EP-3188722-A1 | METHODS FOR TREATING PROTOZOAN INFECTIONS | Neoculi Pty Ltd (AU) | 2017-07-12 | — | — | EP | claimed |
| WO-2016033635-A1 | METHODS FOR TREATING PROTOZOAN INFECTIONS | NEOCULI PTY LTD (AU) | 2016-03-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170291886-A1 | METHODS FOR TREATING PROTOZOAN INFECTIONS | DPM1, ABCB11, PIGS | DUSP3 3658/4885PTPN5 3803/4885PTPN11 4366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.